Sickle cell drug adakveo: what happens when pregnant women take it?
NCT ID NCT07554547
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study looked at pregnancy and baby outcomes in 13 women with sickle cell disease who were treated with Adakveo (crizanlizumab) during pregnancy or shortly before. Researchers tracked rates of miscarriage, stillbirth, and birth defects to better understand the drug's safety during pregnancy. The goal was to gather information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative SIte
Basel, 4056, Switzerland
Conditions
Explore the condition pages connected to this study.